Alentis Therapeutics has secured the investment to fund clinical programs on its two anti-Claudin-1 antibodies for organ fibrosis and CLDN1 positive tumours.

The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.

More details on the BaseLaunch website.

Next >